Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.41+0.01 (+2.12%)
Close on Nov 18, 2026Market cap $113.31MP/E –Yield –
Akebia Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Akebia Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $219.06M, up 7.5% year over year. For fiscal 2025 it was $236.20M, up 47.5% from the year before. The highest annual figure on record is $335.00M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $236.20M | +47.5% |
| FY2024 | Dec 31, 2024 | $160.18M | -17.7% |
| FY2023 | Dec 31, 2023 | $194.62M | -33.5% |
| FY2022 | Dec 31, 2022 | $292.48M | +38.2% |
| FY2021 | Dec 31, 2021 | $211.65M | -28.2% |
| FY2020 | Dec 31, 2020 | $294.64M | -12.0% |
| FY2019 | Dec 31, 2019 | $335.00M | +61.3% |
| FY2018 | Dec 31, 2018 | $207.74M | +14.6% |
| FY2017 | Dec 31, 2017 | $181.23M | +11706.3% |
| FY2016 | Dec 31, 2016 | $1.54M | – |
| FY2015 | Dec 31, 2015 | $0 | – |
| FY2014 | Dec 31, 2014 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $49.13M | -21.4% |
| Q1 FY2026 | Mar 31, 2026 | $53.54M | -6.6% |
| Q4 FY2025 | Dec 31, 2025 | $57.62M | +23.9% |
| Q3 FY2025 | Sep 30, 2025 | $58.77M | +57.0% |
| Q2 FY2025 | Jun 30, 2025 | $62.47M | +43.1% |
| Q1 FY2025 | Mar 31, 2025 | $57.34M | +75.8% |
| Q4 FY2024 | Dec 31, 2024 | $46.50M | -17.3% |
| Q3 FY2024 | Sep 30, 2024 | $37.43M | -11.0% |
| Q2 FY2024 | Jun 30, 2024 | $43.65M | -22.6% |
| Q1 FY2024 | Mar 31, 2024 | $32.61M | -18.5% |
| Q4 FY2023 | Dec 31, 2023 | $56.20M | +0.7% |
| Q3 FY2023 | Sep 30, 2023 | $42.05M | -13.7% |
| Q2 FY2023 | Jun 30, 2023 | $56.38M | -55.4% |
| Q1 FY2023 | Mar 31, 2023 | $40.01M | -35.2% |
| Q4 FY2022 | Dec 31, 2022 | $55.78M | -3.3% |
| Q3 FY2022 | Sep 30, 2022 | $48.71M | -0.1% |
| Q2 FY2022 | Jun 30, 2022 | $126.37M | +138.8% |
| Q1 FY2022 | Mar 31, 2022 | $61.70M | +18.0% |
| Q4 FY2021 | Dec 31, 2021 | $57.68M | +2.9% |
| Q3 FY2021 | Sep 30, 2021 | $48.76M | -18.7% |
| Q2 FY2021 | Jun 30, 2021 | $52.91M | -41.3% |
| Q1 FY2021 | Mar 31, 2021 | $52.30M | -40.9% |
| Q4 FY2020 | Dec 31, 2020 | $56.04M | -19.4% |
| Q3 FY2020 | Sep 30, 2020 | $59.99M | -34.8% |
| Q2 FY2020 | Jun 30, 2020 | $90.14M | -10.6% |
| Q1 FY2020 | Mar 31, 2020 | $88.48M | +21.8% |
| Q4 FY2019 | Dec 31, 2019 | $69.56M | +16.2% |
| Q3 FY2019 | Sep 30, 2019 | $91.98M | +73.0% |
| Q2 FY2019 | Jun 30, 2019 | $100.80M | +106.6% |
| Q1 FY2019 | Mar 31, 2019 | $72.67M | +58.2% |
| Q4 FY2018 | Dec 31, 2018 | $59.85M | -33.9% |
| Q3 FY2018 | Sep 30, 2018 | $53.17M | +28.8% |
| Q2 FY2018 | Jun 30, 2018 | $48.79M | +71.1% |
| Q1 FY2018 | Mar 31, 2018 | $45.93M | +2892.2% |
| Q4 FY2017 | Dec 31, 2017 | $90.56M | – |
| Q3 FY2017 | Sep 30, 2017 | $41.28M | – |
| Q2 FY2017 | Jun 30, 2017 | $28.52M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.54M | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?